אקטוס 15 מג ישראל - עברית - Ministry of Health

אקטוס 15 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 30 מג ישראל - עברית - Ministry of Health

אקטוס 30 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 30 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

אקטוס 45 מג ישראל - עברית - Ministry of Health

אקטוס 45 מג

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 45 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

פיוגליטזון טבע 15 מג ישראל - עברית - Ministry of Health

פיוגליטזון טבע 15 מג

abic marketing ltd, israel - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone

פיוגליטזון טבע 30 מג ישראל - עברית - Ministry of Health

פיוגליטזון טבע 30 מג

abic marketing ltd, israel - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 30 mg - pioglitazone

פיוגליטזון טבע 45 מג ישראל - עברית - Ministry of Health

פיוגליטזון טבע 45 מג

abic marketing ltd, israel - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 45 mg - pioglitazone

פיוגליטזון אינובמד 15  ישראל - עברית - Ministry of Health

פיוגליטזון אינובמד 15

inovamed ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone

פיוגליטזון אינובמד 30  ישראל - עברית - Ministry of Health

פיוגליטזון אינובמד 30

inovamed ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 30 mg - pioglitazone

פיוגליטזון אינובמד 45  ישראל - עברית - Ministry of Health

פיוגליטזון אינובמד 45

inovamed ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 45 mg - pioglitazone

קומפטקט 15 מג  850 מג ישראל - עברית - Ministry of Health

קומפטקט 15 מג 850 מג

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.